Video

CAR-T Cell Therapy: It's Astonishing

Author(s):

Jane N. Winter, M.D.

The time has finally come when researchers have found a way to harness the immune system and use it to fight blood cancers.

Jane N. Winter, M.D., professor of medicine (hematology and oncology) at Northwestern University Feinberg School of Medicine, discusses the excitement surrounding CAR-T cell therapy for the treatment of blood cancers.

Winter is excited that, after generations, researchers have finally harnessed the immune system to treat hematologic malignancies. "When it works, it is astonishing," she said.

Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.
Related Content
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL). Read Chester's blogs here!
March 25th 2025

Navigating a Diagnosis of Diabetes and Chronic Lymphocytic Leukemia

Chester Freeman
Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
FDA grants fast track designation to azer-cel in relapsed/refractory DLBCL: © stock.adobe.com
March 21st 2025

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

Spencer Feldman
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Orca-T improved survival free of moderate-to-severe cGVHD across leukemia subtypes: © nobeastsofierce - stock.adobe.com.
March 18th 2025

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

Spencer Feldman
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
Felicia Mitchell is a survivor of stage 2b HER2-positive breast cancer diagnosed in 2010. Catch up on all of Felicia's blogs here!
March 17th 2025

A Picture is Worth Ten Thousand Words When it Comes to Cancer

Felicia Mitchell
Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.